Join to View Full Profile
450 Brookline AvenueBoston, MA 02215
Phone+1 617-632-3470
Fax+1 617-632-5175
Dr. Odejide is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Oreofe Odejide is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Howard University College of Medicine and has been in practice 9 years. She specializes in hematologic oncology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Howard University College of MedicineClass of 2008
Harvard T.H Chan School of Public HealthMPH, Clinical Effectiveness
Certifications & Licensure
MA State Medical License 2011 - 2025
ME State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- UPLYFT For Lymphoma Survivors Start of enrollment: 2022 Feb 08
Roles: Principal Investigator, Contact
- Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Roles: Contact
- Home Transfusion for HEME Start of enrollment: 2024 Oct 18
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Early Palliative Care, Goals of Care Conversations and Quality EOL Care in Acute Leukemia and HR-MDS.Leonardo Potenza, Davide Giusti, Eleonora Borelli, Elisabetta Colaci, Federico Banchelli
Journal of Pain and Symptom Management. 2025-08-01 - Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S Choi, Stacey M Fernandes
Blood Advances. 2025-06-10 - 7 citationsIntegrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.Javier S Cabrera-Perez, Vincent J Carey, Oreofe O Odejide, Sonal Singh, Thomas S Kupper
The Journal of Allergy and Clinical Immunology. 2025-05-01
Abstracts/Posters
- Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...Oreofe O. Odejide, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Moving Forward When It Is Time to StopASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Fate of Myeloma Drug's Comeback Now Rests in Hands of FDA PanelJuly 15th, 2025- Over a Quarter of Adolescents, Young Adults with Cancer Who Want to Die at Home Do NotFebruary 20th, 2025
- Preferred vs. Actual Location of Death: A Mismatch for Young Cancer PatientsJanuary 14th, 2025
- Join now to see all
Grant Support
- HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic MalignanciesDANA-FARBER CANCER INST2024–2029
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
